Quantum annealer-based molecular docking techniques can be integrated with machine learning pipelines to identify novel therapeutic targets in Multiple Sclerosis by analyzing cross-tissue transcriptomic data.
Adversarial Debate Score
60% survival rate under critique
Model Critiques
Supporting Research Papers
- A Physically-Informed Subgraph Isomorphism Approach to Molecular Docking Using Quantum Annealers
Molecular docking is a crucial step in the development of new drugs as it guides the positioning of a small molecule (ligand) within the pocket of a target protein. In the literature, a feasibility st...
- Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system whose molecular mechanisms remain incompletely understood. In this study, we developed an end-to-end machine learn...
- Unraveling the Mechanism of Drug Binding to SARS-CoV-2 RNA Pseudoknot with Thermodynamics-Driven Machine Learning
The SARS-CoV-2 RNA pseudoknot is a promising target for antiviral intervention, as it regulates the efficiency of -1 programmed ribosomal frameshifting (-1 PRF), a mechanism that is essential for vira...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
A hybrid computational pipeline combining quantum annealer-based molecular docking (specifically using QUBO formulations on D-Wave or equivalent hardware) with supervised/unsupervised machine learning models trained on cross-tissue transcriptomic data (CNS, peripheral blood, lymphoid tissue) will identify ≥3 novel, experimentally tractable therapeutic targets for Multiple Sclerosis that are (a) not currently in clinical trials, (b) show statistically significant differential expression (|log2FC| > 1.5, FDR < 0.05) across ≥2 MS-relevant tissue types, and (c) demonstrate predicted binding affinity improvements of ≥20% over current MS therapeutics (e.g., natalizumab, ocrelizumab reference compounds) in quantum-docked simulations.
- QUANTITATIVE FAILURE: The pipeline identifies <1 novel target meeting all three criteria (differential expression, novelty, binding affinity improvement) after full dataset processing.
- QUANTUM PARITY FAILURE: Quantum annealer-based docking produces binding affinity predictions statistically indistinguishable from classical AutoDock Vina results (paired t-test p > 0.05, Cohen's d < 0.2) across ≥100 benchmark ligand-protein pairs.
- TRANSCRIPTOMIC INCONSISTENCY: Identified targets show differential expression in only 1 tissue type or fail FDR correction when analyzed across the full cross-tissue dataset.
- ML GENERALIZATION FAILURE: ML models achieve AUROC < 0.70 on held-out MS patient data for target prioritization, indicating the pipeline cannot reliably distinguish MS-relevant from irrelevant targets.
- EXPERIMENTAL INVALIDATION: Top 3 predicted targets show no functional effect (IC50 > 100 μM or no significant pathway modulation) in at least 2 independent in vitro MS-relevant cell assays (e.g., oligodendrocyte precursor survival, T-cell activation assays).
- REPRODUCIBILITY FAILURE: Results cannot be reproduced by an independent computational team using the same pipeline and datasets within 15% variance on key metrics.
Experimental Protocol
PHASE 1 — Data Integration and Preprocessing (Weeks 1–4): Collect and harmonize cross-tissue transcriptomic datasets from public repositories (GEO, EMBL-EBI, MSBase) and proprietary sources. Apply batch correction (ComBat-seq), normalize (TMM/DESeq2), and perform quality control filtering. Construct a unified MS transcriptomic atlas covering ≥3 tissue types.
PHASE 2 — Machine Learning Target Prioritization (Weeks 3–8): Train ensemble ML models (Random Forest, Graph Neural Networks on protein interaction networks, and a transformer-based model fine-tuned on MS omics) to rank candidate therapeutic targets. Use cross-validation (5-fold, stratified by disease subtype) and external validation on held-out cohort.
PHASE 3 — Quantum Annealer Docking (Weeks 6–14): Formulate molecular docking as QUBO problems for top 50 ML-prioritized targets. Run on D-Wave Advantage (cloud access via Leap). Benchmark against classical AutoDock Vina on identical protein-ligand pairs. Identify top candidates by predicted ΔG improvement.
PHASE 4 — In Silico Validation (Weeks 12–18): Perform MD simulations (GROMACS, 100 ns trajectories) on top 10 quantum-docked complexes. Assess binding stability (RMSD < 2 Å), ADMET profiling (SwissADME, pkCSM), and off-target liability screening.
PHASE 5 — In Vitro Experimental Validation (Weeks 16–28): Test top 3 targets/compounds in MS-relevant cell assays: oligodendrocyte precursor cell (OPC) differentiation assay, CD4+ T-cell activation/proliferation assay, and microglial cytokine release assay. Minimum n=6 biological replicates per condition.
- GEO Dataset GSE138614: MS brain white matter transcriptomics (n=73 MS, n=25 controls), RNA-seq.
- GEO Dataset GSE193770: PBMC transcriptomics in RRMS patients (n=60 MS, n=40 controls).
- GEO Dataset GSE41849: Cervical lymph node transcriptomics in MS (n=30 MS, n=20 controls).
- MSBase Registry clinical metadata for patient stratification (access via institutional agreement).
- Human Protein Reference Database (HPRD) and STRING v12.0 for protein-protein interaction networks.
- PDB structures for all candidate targets (target: ≥80% of top 50 ML candidates with PDB resolution ≤2.5 Å; remainder via AlphaFold2 DB).
- ChEMBL v33 for known MS-relevant ligand libraries (seed compounds for docking).
- D-Wave Leap cloud quantum computing access (minimum 1,000 QPU hours).
- ZINC20 database subset (FDA-approved + investigational compounds, ~500K molecules) for virtual screening.
- Human GTEx v8 cross-tissue expression reference for baseline normalization.
- ML Model Performance: Ensemble AUROC ≥ 0.80 on held-out validation set for MS target prioritization.
- Target Novelty: ≥3 identified targets not listed in ClinicalTrials.gov as MS therapeutic targets (as of validation date) and not in current MS drug labels.
- Cross-Tissue Expression: ≥3 targets show |log2FC| > 1.5, FDR < 0.05 in ≥2 of 3 tissue types.
- Quantum Docking Advantage: Quantum annealer identifies binding poses with predicted ΔG ≥ 20% lower (more favorable) than AutoDock Vina for ≥30% of tested ligand-protein pairs.
- MD Stability: ≥5 of top 10 docked complexes maintain RMSD < 2 Å over final 50 ns of MD simulation.
- ADMET Compliance: ≥2 of top 3 compounds pass all Lipinski criteria and show predicted BBB permeability > -1 log BB (if CNS target).
- In Vitro Efficacy: ≥2 of top 3 compounds show statistically significant effect (p < 0.05, Cohen's d > 0.5) in ≥2 of 3 cell assays at concentrations ≤10 μM.
- Reproducibility: Independent replication achieves ≥85% concordance on top 20 ranked targets.
- ML AUROC < 0.70 on held-out validation set after hyperparameter optimization.
- Zero novel targets identified (all top candidates already in MS clinical trials or approved drugs).
- Quantum docking ΔG predictions not significantly different from AutoDock Vina (p > 0.05, paired test across ≥100 pairs).
- All top 10 MD simulations show RMSD > 3 Å (unstable binding).
- All top 3 compounds fail ADMET screening (>2 Lipinski violations or predicted hERG IC50 < 1 μM).
- No compound shows in vitro efficacy at ≤50 μM in any of the 3 cell assays.
- Independent replication achieves <70% concordance on top 20 ranked targets.
- Quantum hardware unavailability exceeds 4 weeks, preventing completion of docking phase.
2,400
GPU hours
196d
Time to result
$47,000
Min cost
$215,000
Full cost
ROI Projection
- LICENSING: Quantum-ML docking pipeline licensable to pharmaceutical companies at $2M–$10M per license; estimated 5–15 licensees in 5 years = $10M–$150M licensing revenue.
- BIOTECH SPINOUT: Pipeline could anchor a computational drug discovery startup; comparable companies (Insilico Medicine, Exscientia) valued at $400M–$2B at Series B.
- DIAGNOSTIC APPLICATIONS: Cross-tissue transcriptomic atlas of MS could be commercialized as a companion diagnostic or patient stratification tool ($50M–$200M market).
- QUANTUM COMPUTING SECTOR: Validates a concrete pharmaceutical use case for quantum annealers, potentially increasing D-Wave/IonQ enterprise contract values; indirect commercial value to quantum hardware sector estimated $100M–$500M in accelerated adoption.
- CRO SERVICES: Methodology could be offered as a fee-for-service computational drug discovery offering at $500K–$2M per target identification project.
- DATA ASSET: Harmonized cross-tissue MS transcriptomic atlas (if proprietary data included) has standalone value of $5M–$20M to pharmaceutical partners.
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1MS-INVIVO-VALIDATION-021
- 2QUANTUM-PHARMA-PIPELINE-GENERALIZATION-034
- 3CROSS-TISSUE-TARGET-DISCOVERY-AUTOIMMUNE-045
- 4QUANTUM-ML-DRUG-DISCOVERY-PLATFORM-056
- 5MS-BIOMARKER-PANEL-DEVELOPMENT-067
Prerequisites
These must be validated before this hypothesis can be confirmed:
- QA-MOLEC-DOCK-001
- MS-TRANSCRIPTOMICS-ATLAS-003
- QUBO-PROTEIN-FORMULATION-007
- ML-OMICS-PRIORITIZATION-012
Implementation Sketch
# QUANTUM-ML MS TARGET DISCOVERY PIPELINE # Architecture Overview ## MODULE 1: DATA INTEGRATION class MSTranscriptomicAtlas: def __init__(self, geo_ids, tissue_types): self.datasets = {tissue: load_geo(id) for tissue, id in zip(tissue_types, geo_ids)} self.tissues = ['white_matter', 'PBMC', 'lymph_node'] def preprocess(self): for tissue, data in self.datasets.items(): data = fastqc_filter(data, min_rin=6, min_mapping_rate=0.75) data = combatseq_correct(data, batch_var='study_id') data = deseq2_normalize(data) return self.merge_tissues() # Returns unified atlas: [n_genes x n_samples x n_tissues] def differential_expression(self): # Per-tissue DESeq2 de_results = {} for tissue in self.tissues: de_results[tissue] = deseq2_de( counts=self.datasets[tissue], design='~ condition', # MS vs control contrast=['condition', 'MS', 'control'] ) # Cross-tissue filter: |log2FC| > 1.5, FDR < 0.05 in >= 2 tissues cross_tissue_targets = filter_cross_tissue(de_results, log2fc_threshold=1.5, fdr_threshold=0.05, min_tissues=2) return cross_tissue_targets # Expected: 200-800 genes ## MODULE 2: ML TARGET PRIORITIZATION class EnsembleTargetPrioritizer: def __init__(self, targets, ppi_network): self.targets = targets self.network = ppi_network # STRING v12.0 def build_features(self, gene): return { 'cross_tissue_log2fc': [de_results[t][gene]['log2FC'] for t in tissues], 'betweenness_centrality': nx.betweenness_centrality(self.network)[gene], 'druggability_score': dgidb_query(gene), 'tissue_specificity_tau': compute_tau(gene, gtex_data), 'pathway_enrichment': gsea_score(gene, hallmark_genesets), 'ppi_degree': self.network.degree(gene), 'known_ms_proximity': rwr_score(gene, ms_seed_genes, restart=0.7) } def train(self, labeled_data): # Labeled data: known MS targets (positive) + random non-targets (negative) X = np.array([self.build_features(g) for g in labeled_data.genes]) y = labeled_data.labels # Base models self.rf = RandomForestClassifier(n_estimators=500, max_depth=10) self.gat = GraphAttentionNetwork(layers=3, hidden_dim=128, heads=4) self.biobert = FineTunedBioBERT(task='gene_disease_association') # Stacking ensemble base_preds = cross_val_predict([self.rf, self.gat, self.biobert], X, y, cv=5) self.meta_learner = LogisticRegression().fit(base_preds, y) def prioritize(self, candidates): scores = self.meta_learner.predict_proba( [self.build_features(g) for g in candidates] )[:, 1] return sorted(zip(candidates, scores), key=lambda x: -x[1])[:50] ## MODULE 3: QUANTUM ANNEALER DOCKING class QuantumDockingEngine: def __init__(self, sampler='DWaveCliqueSampler'): import dwave.system as dw self.sampler = dw.DWaveCliqueSampler() # D-Wave Advantage self.annealing_time = 20 # microseconds self.num_reads = 1000 def encode_ligand_qubo(self, ligand, protein, grid_resolution=0.375): """ Encode docking as QUBO problem. Binary variables: torsion angles (3-bit per rotatable bond) + translation (6-bit per axis) + rotation (quaternion, 8-bit) """ n_torsions = count_rotatable_bonds(ligand) # Limit: <= 15 n_vars = n_torsions * 3 + 6*3 + 8 # Total binary variables Q = {} # QUBO matrix # Van der Waals energy terms Q = add_vdw_terms(Q, ligand, protein, grid_resolution) # Electrostatic terms Q = add_electrostatic_terms(Q, ligand, protein) # H-bond terms Q = add_hbond_terms(Q, ligand, protein) # Clash penalty (hard constraint) Q = add_clash_penalty(Q, ligand, protein, penalty=1000) return Q, n_vars def dock(self, ligand, protein): Q, n_vars = self.encode_ligand_qubo(ligand, protein) # Submit to D-Wave response = self.sampler.sample_qubo( Q, num_reads=self.num_reads, annealing_time=self.annealing_time, chain_strength=auto_chain_strength(Q) ) # Decode best solution best_sample = response.first.sample pose = decode_pose(best_sample, ligand) delta_g = calculate_binding_energy(pose, protein) return pose, delta_g def benchmark_vs_classical(self, test_pairs): """Compare quantum vs AutoDock Vina on identical pairs""" quantum_dg = [self.dock(l, p)[1] for l, p in test_pairs] classical_dg = [autodock_vina(l, p, exhaustiveness=32) for l, p in test_pairs] stat, pval = wilcoxon(quantum_dg, classical_dg) improvement = np.mean([(q-c)/abs(c) for q,c in zip(quantum_dg, classical_dg)]) return {'p_value': pval, 'mean_improvement': improvement, 'n_pairs': len(test_pairs)} ## MODULE 4: MD VALIDATION class MDValidator: def run_simulation(self, complex_pdb, duration_ns=100): """GROMACS MD simulation""" # Setup: CHARMM36 FF, TIP3P water, 150mM NaCl, NPT system = gromacs_setup(complex_pdb, forcefield='charmm36', water='tip3p', salt_conc=0.150, ensemble='NPT') trajectory = gromacs_run(system, duration_ns=duration_ns) rmsd = calculate_rmsd(trajectory, reference='initial', selection='ligand', start_ns=50) binding_fe = mmpbsa(trajectory, complex_pdb) return {'rmsd_mean': np.mean(rmsd), 'rmsd_std': np.std(rmsd), 'binding_fe': binding_fe, 'stable': np.mean(rmsd) < 2.0} ## MODULE 5: PIPELINE ORCHESTRATION def run_full_pipeline(): # Step 1: Build atlas atlas = MSTranscriptomicAtlas(GEO_IDS, TISSUE_TYPES) atlas.preprocess() candidates = atlas.differential_expression() # 200-800 genes # Step 2: ML prioritization prioritizer = EnsembleTargetPrioritizer(candidates, load_string_network()) prioritizer.train(load_ms_labeled_data()) top_50 = prioritizer.prioritize(candidates) # Step 3: Filter for druggability + structure dockable = [t for t in top_50 if has_3d_structure(t) and druggability(t) > 0.4] # Step 4: Quantum docking qde = QuantumDockingEngine() docking_results = {} for target in dockable: protein = load_structure(target) ligands = screen_zinc20(target, n_compounds=1000) best_poses = [qde.dock(l, protein) for l in ligands] docking_results[target] = sorted(best_poses, key=lambda x: x[1])[:5] # Step 5: Benchmark benchmark = qde.benchmark_vs_classical(generate_benchmark_pairs(100)) # Step 6: MD validation of top 10 top_10_complexes = get_top_complexes(docking_results, n=10) md_results = {c: MDValidator().run_simulation(c) for c in top_10_complexes} # Step 7: ADMET filtering top_3 = admet_filter(top_10_complexes, md_results)[:3] # Step 8: Report return generate_evp_report(top_3, benchmark, md_results) # RESOURCE ALLOCATION COMPUTE_CONFIG = { 'gpu_cluster': 'A100 x 8 (ML training + MD)', 'quantum_hardware': 'D-Wave Advantage (Leap cloud)', 'cpu_cluster': '256 cores (preprocessing + docking classical benchmark)', 'storage': '20 TB (raw + processed transcriptomics + trajectories)', 'timeline_days': 196 }
CHECKPOINT 1 — End of Week 2 (Data QC): ABORT IF: >40% of samples fail QC filters across any tissue type, leaving <30 MS patients per tissue. Action: Seek additional datasets before proceeding; do not continue with underpowered cohort.
CHECKPOINT 2 — End of Week 6 (ML Validation): ABORT IF: Best single ML model achieves AUROC < 0.65 on 5-fold CV. Action: Reassess feature engineering, consider alternative model architectures, or expand training data before proceeding to quantum docking phase.
CHECKPOINT 3 — End of Week 8 (Quantum Benchmark Preliminary): ABORT IF: Preliminary quantum docking benchmark (n=20 pairs) shows quantum ΔG predictions have correlation r < 0.3 with experimental binding affinities from ChEMBL. Action